Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Medimmune Limited patents


Recent patent applications related to Medimmune Limited. Medimmune Limited is listed as an Agent/Assignee. Note: Medimmune Limited may have other listings under different names/spellings. We're not affiliated with Medimmune Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medimmune Limited-related inventors


 new patent  Human antibody molecules for il-13

Specific binding members, in particular human anti-il-13 antibody molecules and especially those which neutralize il-13 activity. Methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma.. ... Medimmune Limited

 new patent  Targeted pyrrolobenzodiazapine conjugates

Provided are conjugate comprising pbds conjugated to a targeting agent and methods of using such pbds.. . ... Medimmune Limited

Compounds and methods for treating pain

. . This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an ngf antagonist and a tnfα antagonist. ... Medimmune Limited

Ctla-4 variants

Variants of cytotoxic t-lymphocyte antigen 4 (ctla-4) with high affinity, potency and stability. Formulations of ctla-4 variants at high concentration for subcutaneous or intravenous administration, e.g. ... Medimmune Limited

A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

The present invention provides isolated il-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against il-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.. ... Medimmune Limited

Binding molecules specific for cd73 and uses thereof

The present disclosure provides anti-cd73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with cd73-expression, e.g., cancer. ... Medimmune Limited

Pyrrolobenzodiazepine-antibody conjugates

Conjugates of an antibody that binds to cd25 with pbd dimers.. . ... Medimmune Limited

Pyrrolobenzodiazepine-anti-cd22 antibody conjugates

Conjugates of an isolated humanized, anti-cd22 antibody with pbd dimers.. . ... Medimmune Limited

Compounds

Binding members, e.g. Human antibody molecules, which bind interleukin-6 (il-6 ) and neutralise its biological effects. ... Medimmune Limited

Protease-resistant lipidated glp-1 analogs

The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. A combination of lipidation of certain amino acid residues and substitution of alpha-methyl functionalized amino acids for natural amino acids has been determined to produce protease-resistant peptides.. ... Medimmune Limited

Novel phage display library, members thereof and uses of the same

The present invention relates to a library (in particular a phage display library) from which an improved human antibody having greater specificity and potency for its target may be generated; and to methods of generating such a human antibody. In particular, the invention relates to a human antibodies against challenging targets obtainable from such a library and which have hcdr3s of at least 18 amino acids in length.. ... Medimmune Limited

Combination therapy for non-small cell lung cancer positive for egfr mutation

The present invention features methods of treating lung cancer (e.g., nsclc) with an anti-pd-l1 antibody and a tyrosine kinase inhibitor in a subject identified as having an egfr mutation-positive tumor.. . ... Medimmune Limited

Pyrrolobenzodiazepines and conjugates thereof

Conjugates and compounds for making conjugates which are pbd molecules linked via the n10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.. . ... Medimmune Limited

Therapeutic combinations comprising anti-cd73 antibodies and uses thereof

The present invention provides therapeutic combinations featuring anti-cd73 antibodies (e.g., med19447) and a2a receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.. . ... Medimmune Limited

05/03/18 / #20180117172

Site-specific antibody-drug conjugates

Site-specific anti-body-drug conjugates are described, in particular conjugates comprising an antibody, which binds her2 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Limited

04/19/18 / #20180105585

Antibodies to amyloid beta

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. ... Medimmune Limited

04/12/18 / #20180099055

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds cd25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Limited

04/05/18 / #20180092986

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds cd19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Limited

04/05/18 / #20180092985

Site-specific antibody-drug conjugates

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the adc.. ... Medimmune Limited

03/22/18 / #20180079814

Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer

A method for treating lung cancer (e.g., non-small cell lung cancer) with an anti-pd-l1 antibody (medi4736), alone or in combination with an anti-ctla4 antibody (tremelimumab), in a patient identified using a polynucleotide marker of ifngamma.. . ... Medimmune Limited

03/01/18 / #20180057605

Blood brain barrier transport molecules and uses thereof

The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.. ... Medimmune Limited

03/01/18 / #20180057596

Binding members of interleukin-4 receptor alpha (il4-ra)

Binding members, especially antibody molecules, for interleukin (il)-4 receptor alpha (il-4rα), and their therapeutic use e.g., in treating or preventing disorders associated with il-4rα, il-4 and/or il-13, examples of which are asthma and copd.. . ... Medimmune Limited

01/04/18 / #20180002411

Antibodies to alpha-synuclein and uses thereof

The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.. . ... Medimmune Limited

11/30/17 / #20170342121

Glucagon/glp-1 agonists for the treatment of obesity

This disclosure provides glp-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.. . ... Medimmune Limited

11/30/17 / #20170340752

Pyrrolobenzodiazepines and conjugates thereof

A conjugate of formula (a): wherein y is selected from formulae a1 and a2: z1 is a c1-3 alkylene group; z2 is a c1-3 alkylene group; q is: where qx is such that q is an amino-acid residue, a dipeptide residue or a tripeptide residue; l is a linker connected to a cell binding agent; cba is the cell binding agent; and n is an integer between 0 and 48.. . ... Medimmune Limited

11/09/17 / #20170320954

Therapeutic combinations and methods for treating neoplasia

The disclosure features a cxcr2 antagonist in combination with a checkpoint inhibitor (e.g., an anti-ctla-4 antibody or an anti-pd-l1 antibody) and methods of using the combination to enhance anti-tumor activity in a subject.. . ... Medimmune Limited

10/26/17 / #20170306381

Cell lines

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses pylrs and trnapyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of trnapyl expression on cell viability and/or cell growth is reduced or eliminated.. . ... Medimmune Limited

10/26/17 / #20170306380

Amino acid derivatives

There are provided amino acid derivatives of formula v and vi as defined herein which are pyrrolysine analogs for use in bioconjugation processes.. . ... Medimmune Limited

10/26/17 / #20170304343

Binding proteins specific for lox1 and uses thereof

This disclosure provides lox1 (lox1) binding proteins such as anti-lox1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the lox1-binding proteins provided herein, inhibit, or antagonize lox1 activity. ... Medimmune Limited

10/05/17 / #20170281769

Stable anti-il-4ra formulation

. . The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-il4r antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/ml to about 200 mg/ml of an antibody or fragment thereof that specifically binds human interleukin-4 receptor alpha (hil-4rα), about 50 mm to about 400 mm of a viscosity modifier; about 0.002% to about 0.2% of a non-ionic surfactant; and a formulation buffer. ... Medimmune Limited

09/28/17 / #20170275347

Methods for identifying patients responsive to anti-pd-l1 antibody therapy

The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-pd-l1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: cxcl9, krt8, trim29, and/or ifngamma.. . ... Medimmune Limited

09/21/17 / #20170267778

Humanized anti-tn-muc1 antibodies and their conjugates

Humanized anti-tn-muc1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (pbds) having a labile protecting group in the form of a linker to the antibody are described.. ... Medimmune Limited

09/14/17 / #20170260276

Treatment for rheumatoid arthritis

Treatment of rheumatoid arthritis (ra) to provide clinical benefit in patients, including decrease in das28-crp by more than 1.2 and/or improvement determined by acr20, acr50 or acr70, comprising administering therapeutic antibody mavrilimumab.. . ... Medimmune Limited

09/14/17 / #20170258934

Pyrrolobenzodiazepine-antibody conjugates

The present disclosure relates to the use of antibody-drug conjugates (adcs) comprising pyrrolobenzodiazepine (pbd) dimers and anti-cd25 antibodies for use in treating disorders characterized by the presence of cd25+ve cells.. . ... Medimmune Limited

08/24/17 / #20170239365

Pyrrolobenzodiazepines and conjugates thereof

A conjugate comprising a pbd dimer linked from the tether joining the two pbd units, wherein the linker is of formula (a1): (formula (a1)) wherein rn1 is selected from h and c1-4 alkyl; l is a linker connected to a cell binding agent; cba is the cell binding agent; n is an integer selected in the range of 0 to 48; q is: (formula (q)), where qx is such that q is an amino-acid residue, a dipeptide residue or a tripeptide residue.. . ... Medimmune Limited

08/10/17 / #20170226158

Intracellular antigen binding

The disclosure generally provides a designed ankyrin repeat protein (darpin) that specifically binds to an antigen, the darpin having an n-terminal cap section, at least two ankyrin repeat (ar) module sections, and a c-terminal cap section, characterized in that the darpin has a charge that is less negative than known 5 darpins. The disclosure also provides for generation of a library of the less negative darpins.. ... Medimmune Limited

06/29/17 / #20170183397

Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof

This disclosure relates to combination therapies comprising anti-pseudomonas psl and pcrv bispecific binding molecules and related compositions, for use in prevention and treatment of pseudomonas infection.. . ... Medimmune Limited

06/22/17 / #20170174756

Stabilized angiopoietin-2 antibodies and uses thereof

Stabilized antibodies directed to angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.. ... Medimmune Limited

06/15/17 / #20170166634

Ion channel modulators and uses thereof

The invention provides antibodies that specifically bind a p2x4 polypeptide and modulate p2x4 channel activity, recombinant p2x4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-p2x4 antibodies, and methods of using p2x4 antibodies for the treatment of neuropathic pain and other indications.. . ... Medimmune Limited

05/18/17 / #20170137522

Targeted binding agents against b7-h1

Human monoclonal antibodies directed against b7-h1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of b7-h1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.. ... Medimmune Limited

04/27/17 / #20170114151

Multispecific and multivalent binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.. ... Medimmune Limited

04/13/17 / #20170101468

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.. ... Medimmune Limited

03/16/17 / #20170073386

Gitrl fusion proteins and uses thereof

The disclosure provides gitrl fusion polypeptide subunits comprising an igg fc domain, a trimerization domain, and the receptor binding domain of gitr ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.. ... Medimmune Limited

02/02/17 / #20170029499

Methods for treating hepcidin-mediated disorders

Methods for treating hepcidin-mediated disorders are provided.. . ... Medimmune Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Medimmune Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medimmune Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###